title: Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia.
abstract: Optimizing treatment for patients with persistent low-level viremia is complicated because most genotyping tests are validated for viral loads >1000 copies per milliliter. In this study, genotypes of 92 treatment-experienced patients with persistent low-level viremia were determined using an in-house assay. Based on the resistance profiles obtained from genotyping and patient pharmacologic history, patients were either maintained on their antiviral regimen (n = 51) or received an optimized regimen (n = 41). In the group receiving optimized treatment, undetectable viral loads were achieved in 73.2% at 6 months and at 90.2% at 1 year, indicating that treatment guided by genotyping of patients with low-level viremia is effective in achieving viral suppression.
authors.affiliation: Unit of Infectious Diseases, Microbiology and Preventive Medicine, Instituto de Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: McConnell
authors.forename: Julian
authors.initials: J
authors.lastname: Mier-Mota
authors.forename: Fernando
authors.initials: F
authors.lastname: Flor-Parra
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Martinez-Fernandez
authors.forename: Luis F
authors.initials: LF
authors.lastname: Lopez-Cortes
authors.forename: Pompeyo
authors.initials: P
authors.lastname: Viciana
authors.forename: Felipe
authors.initials: F
authors.lastname: Fernandez-Cuenca
authors.forename: Pilar
authors.initials: P
authors.lastname: Perez-Romero
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015967:Gene Expression Regulation, Viral; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D016333:HIV Protease / Q000235:genetics / Q000378:metabolism; D054303:HIV Reverse Transcriptase / Q000235:genetics / Q000378:metabolism; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D019562:Viral Load / Q000187:drug effects / Q000235:genetics; D014766:Viremia / Q000097:blood* / Q000235:genetics
chemical_list: D019380:Anti-HIV Agents; D054303:HIV Reverse Transcriptase; D016333:HIV Protease